Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure

Area of Science:

• Biochemistry
• Molecular Biology
• Structural Biology

Background:

• Janus Kinase 2 (JAK2) is crucial for cytokine receptor signaling.
• Constitutive JAK2 activation leads to hematopoietic disorders and cancer.
• The pseudokinase domain (JH2) regulates JAK2 activity, and the V617F mutation in JH2 causes myeloproliferative neoplasms.

Purpose of the Study:

• To elucidate the structural mechanism of JAK2 auto-inhibition by its JH2 domain.
• To understand how the V617F mutation in JH2 leads to JAK2 hyperactivation.
• To provide a structural basis for developing JAK2-targeted therapies.

Main Methods:

• Informatics-guided protein-protein docking to model the JAK2 JH1-JH2 complex structure.
• Computational modeling to propose a detailed auto-inhibition mechanism.
• Site-directed mutagenesis and cell transformation studies (BaF3/EpoR) to validate predicted interactions.

Main Results:

• A structural model of the JAK2 JH1-JH2 complex was generated.
• A novel JAK2 auto-inhibition mechanism is proposed, involving JH2 trapping of the JH1 activation loop and blocking of the αC helix.
• The V617F mutation destabilizes these inhibitory interactions, leading to hyperactivation.
• Mutagenesis studies confirmed key residues in JH2 that modulate JAK2 kinase activity.

Conclusions:

• The proposed JH1-JH2 structural model provides a working hypothesis for JAK2 regulation.
• Understanding JH2's inhibitory role is critical for comprehending JAK2-driven oncogenesis.
• This study lays the groundwork for further experimental validation and therapeutic development targeting JAK2.